92764-04-0

Basic information

• Product Name: Imidazolidinetrione, (2-phenylethyl)-
• CAS NO: 92764-04-0
• Molecular Formula: C11H10N2O3
• Molecular Weight: 218.212
• Mol File: 92764-04-0.mol

Chemical Properties

• CAS DataBase Reference: Imidazolidinetrione, (2-phenylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazolidinetrione, (2-phenylethyl)-(92764-04-0)
• EPA Substance Registry System: Imidazolidinetrione, (2-phenylethyl)-(92764-04-0)

Safety Data

• Hazardous Substances Data: 92764-04-0(Hazardous Substances Data)

Upstream product

• 2158-04-5 (2-phenylethyl)urea 
• 95-92-1 oxalic acid diethyl ester 
• 79-37-8 oxalyl dichloride 
• 156-28-5 2-phenylethylamine hydrochloride 
• 64-04-0 phenethylamine 

Downstream Products

• 92764-10-8 3-(2-phenethyl)-5-hydroxyimidazolidine-2,4-dione 
• 92764-09-5 1-(2-phenethyl)-5-hydroxyimidazolidine-2,4-dione 
• 128043-74-3 ethyl (2,4,5-trioxo-3-phenethyl-imidazolidin-1-yl)ethanoate 
• 1027172-85-5 3-(2,4,5-trioxo-3-phenethyl-imidazolidin-1-yl)-propionamide 

Relevant articles and documents

Structure-activity relationship of 2,4,5-trioxoimidazolidines as inhibitors of thymidine phosphorylase

Novel non-nucleobase-derived inhibitors of the angiogenic enzyme, thymidine phosphorylase, have been identified using molecular modelling, synthesis and biological evaluation. These inhibitors are 2,4,5-trioxoimidazolidines bearing N-(substituted)phenylalkyl groups, together with, in most cases, N′-(CH2)n-carboxylic acid, ester or amide side chains. The best compound from this series is 3-(2,4,5-trioxo-3-phenylethyl- imidazolodin-1-yl)propionamide, with an IC50 of 40 μM against Escherichia coli TP. Molecular modelling suggests that this ligand, when complexed with closed-cleft human TP, would have the phenylalkyl group in the active site region normally occupied by a thymine-containing structure.

Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5- trioxoimidazolidine-1-acetic acids

A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)IC50(AR) was > 1000 in some compounds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5- trioxoimidazolidine-1-acetic acid (NZ-314) was selected as the candidate for clinical development.

Synthesis of Substituted 2-Imidazolidinones and Annelated Hydantions via Aminoalkylation Transformations

The synthetic utility of 4-hydroxy-2-imidazolidinone amidoalkylation reactions is limited by the propensity of the carbon-5 unsubstituted and carbon-5 monosubstituted adducts to undergo dehydration to yield 2-imidazolones.Two techniques are reported which